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Abstract
Background: Uremic neuropathy is a common complication in patients with end stage kidney disease. Its
pathogenesis has been attributed to accumulation of uremic toxins. Kidney transplantation has been the best
therapeutic option.
Case presentation: We describe a case of severe uremic peripheral neuropathy, which improved after conversion
from a conventional renal replacement therapy to nocturnal hemodialysis.
Conclusion: Enhanced uremic control by intensive hemodialysis may contribute at least in part to clinical and
neurophysiological improvements of uremic neuropathy.
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Background
Uremic peripheral neuropathy is a common condition
amongst patients with end stage kidney disease (ESKD),
which in most cases is progressive, and in some sig-
nificantly debilitating. At present, renal transplant-
ation remains the best therapeutic option for uremic
neuropathy [1, 2].
We report the clinical and electrophysiologic findings in
a man with this disorder who demonstrated significant im-
provement after conversion to nocturnal hemodialysis.
Case Report
A 48 year old man with ESKD presented with severe de-
creased sensation in his bilateral feet, originated from
bottom of his feet, and gradually advanced to above the
ankle level over the course of 2–3 years.
He reported the sensation of “walking on cushions”, as
well as progressive difficulty with ambulation. Addition-
ally, he complained of ongoing pain in bilateral legs, as
well as dysaesthesia in bilateral hands. He had been diag-
nosed with ESKD at age 37, secondary to poorly con-
trolled hypertension. He was initiated on peritoneal
dialysis (PD) therapy for two years, before receiving a
living-related-donor kidney transplant at age 39. His
renal graft failed due to chronic allograft nephropathy
after 7 years, when he had to be restarted on PD for
renal replacement therapy. He had been on PD therapy
for 4 years at the time of presenting with above symp-
toms. He had minimal residual urine output during the
last 2 years of PD. As a result, he was receiving continu-
ous cycling peritoneal dialysis (CCPD), 8 liters over
9 hours overnight, with a last fill of 1.5 L, with good
compliance. Membrane transport type with 4-hour peri-
toneal equilibrium test (PET) was high average. His past
medical history included a remote history of malarial in-
fection, gout and native kidney nephrectomy due to
findings of a mass compatible with renal cell carcinoma
on post-operative pathology report, one year prior to
current presentation.
He also had been diagnosed with type 2 diabetes melli-
tus one year prior to the above presentation, and had ap-
propriate glycemic control achieved by diet and lifestyle
modifications. He denied any history of thyroid disease,
vitamin deficiencies, lyme disease, alcohol abuse, chemo-
therapy, heavy metal exposure, amyloidosis or other
systemic `diseases. There was no previous history of
peripheral vascular disease. His medications included
prednisone, verapamil, calcium carbonate, atorvastatin,
darbepoetin injection, multivitamin tablet and venlafax-
ine. Cyclosporine and Mycophenolate Mofetil had been
discontinued for 3 years prior to the above presentation.
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On physical examination, his vital signs were stable;
examination of head and neck, heart, lungs and abdomen
was unremarkable. On neurologic exam, there was no evi-
dence of muscle atrophy or fasciculations. The deep ten-
don reflexes were absent throughout. Sensory exam was
significantly abnormal; pinprick and light touch sensations
were impaired up to level of mid-calf bilaterally, there was
moderate deficit of joint position sensation at the toes.
Vibration thresholds were measured 50 microns on right
great toe, and 38 microns on the left. Gait was promin-
ently antalgic, but otherwise without specific characteris-
tics. Muscle strengths were found to be symmetrical and
5/5 bilaterally. Cranial nerves were intact. The rest of
physical exam was unremarkable.
His initial laboratory testing showed abnormalities
consistent with ESKD: blood urea nitrogen above
10 mmol/L and serum creatinine above 1000 umol/L,
for the previous several years. HbA1C had been less than
7 % consistently. Hemoglobin averaged around 100 g/L,
potassium 3.7 mmol/L, corrected calcium 2.4 mmol/L
and phosphate 1.7 mmol/L. Average weekly Kt/V for PD,
as an adequacy index was 2.84.
Nerve conduction studies were performed, results of
which were compatible with a severe, length-dependent,
combined demyelinating and axonal, sensorimotor poly-
neuropathy. This was deemed to be most in keeping
with uremic neuropathy. Although the patient had been
diagnosed with diabetes the year before this presenta-
tion, the short duration of the disease and absence of
other complications of diabetes, made the diagnosis of
diabetic neuropathy unlikely. Given the patient’s severity
of clinical symptoms , despite a reasonable accepted ad-
equacy for peritoneal dialysis, it was decided to convert
his renal replacement therapy to Nocturnal Home
hemodialysis (NHD) 5–6 nights per week, 7–8 hours per
session of dialysis. We hypothesize that an increase in
uremic clearance may improve his uremic neuropathy.
Within 6 months following the switch to NHD, the pa-
tient reported significant improvement of dysaesthesia,
with reduction in leg pain and improvement in his
ambulation.
Routine laboratory values showed improvement in dialy-
sis parameters, including average hemoglobin of 121 g/L,
potassium of 4 mmol/L, creatinine of 540 mmol/L, blood
urea nitrogen of 10 mmol/L, corrected calcium of 2.40
and phosphate of 0.8 mmol/L.
Repeat sensory and motor nerve conduction studies
were performed 1 and 2 years after conversion to
NHD; there were improvements in nerve conduction
velocity, amplitude and latency measures, in both sen-
sory and motor components. The neurophysiological
improvements were more pronounced in the upper
extremities. These findings were consistent with reso-
lution of symptoms.
Figures 1 and 2 demonstrate motor and sensory nerve
conduction studies at baseline and after conversion to
NHD.
Discussion
Uremic neuropathy is a common condition in patients
with ESKD. The prevalence ranges from 60–93 % in the
dialysis population [3]. In non-dialysis patients with
chronic kidney disease (CKD), the prevalence was re-
ported to be 64 % in one study [4].
Uremic neuropathy typically presents as a slowly pro-
gressive sensorimotor axonal neuropathy. Other forms
of neuropathy described include a rapidly progressive
motor neuropathy, and a small fibre neuropathy, which
are rarer in presentation. The clinical manifestations of
uremic neuropathy may vary. Some patients may notice
primarily sensory symptoms early in the disease, which
may present as paraesthesia, pain, or loss of sensitivity.
Loss of deep tendon reflexes has also been described.
With progression, there is increasing motor involve-
ment, with muscle atrophy and loss of strength. Symp-
toms progress proximally, with involvement of the upper
limbs occurring after lower limb involvement. The
underlying pathology is believed to be due to a demye-
linating process, and is contributed by axonal degener-
ation and loss.
Various neurophysiological findings are associated
with uremic neuropathy, and nerve conduction studies
remain the gold standard for its diagnosis. In general,
neuropathies that result in axonal degeneration result in
conduction velocities that are mildly reduced. Values
typically are reduced but remained above the threshold
of 30 ms−1 in the lower limbs, and 35 ms−1 in the upper
limbs. In contrast, for demyelinating lesions, values are
generally expected to be substantially lower. In addition,
the amplitude of evoked potentials is reduced in axonal
degeneration, whereas it would be expected to be rela-
tively preserved in demyelinating lesions. Early studies in
motor nerve conduction parameters demonstrated a
slowing of conduction velocities. Other studies demon-
strated a generalized slowing in both sensory and motor
nerves, with reductions in sensory response amplitudes [5].
More recently, Krishnan et al. have described a change
in sural sensory potential as being the most sensitive
nerve conduction abnormality in patients with CKD [6].
Improvements of uremic neuropathy with dialysis and
transplantation have been described. Early observational
studies demonstrated a reduction in the prevalence of
neuropathy with either an increase in frequency or dose of
dialysis [7]. As a result, investigators hypothesize that
uremic toxin(s) contribute, at least in part, to the pa-
thogenesis of uremic neuropathy. Both peritoneal and
conventional hemodialysis have demonstrated partial effi-
cacy in reducing the progression of uremic neuropathy.
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Fig. 1 Motor nerve conduction velocities. Before conversion to NHD, 1 year after conversion and 2 years after conversion
Fig. 2 Sensory nerve conduction velocities. Before conversion to NHD, 1 year after conversion and 2 years after conversion. (R: Right)
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Recently, hemodiafiltration has been associated with a re-
duction in motor nerve excitability parameters as com-
pared to patients on high flux hemodialysis, both after a
single session, and longitudinally [8]. To date, renal trans-
plantation has been the preferred therapeutic option to
provide either a “cure” or an improvement in the severity
of uremic neuropathy. As early as the 1970s, Bolton et al.
reported functional recovery in 3 out of 10 patients post
transplantation, even though residual clinical signs and
electrophysiological abnormalities remain [1]. Other pa-
tients either had moderate recovery, or subclinical im-
provement reflected by nerve conduction velocities.
Similarly, Hupperts et al. reported two patients that had
either partial or complete recovery of uremic neuropathy
post renal transplantation [9]. Consistent reports were also
reported in the pediatric population [10].
To our knowledge, this is the first description of a pa-
tient with uremic neuropathy who demonstrated both
clinical and neurophysiological improvements after con-
verting from conventional renal replacement therapy to
NHD. Our results add to the existing literature, which
suggests that accumulated uremic toxins are responsible
for the progression of uremic neuropathy. The use of in-
tensive hemodialysis offers another potential therapeutic
option to achieve the necessary clearances associated with
amelioration of neurological symptoms. Given that NHD
provides augmented uremic clearance in comparison to all
forms of conventional renal replacement therapy, it is
tempting to speculate that our present case report is a dir-
ect result of enhanced toxin removal. Equally important,
other authors have proposed the role of physiological
maintenance of electrolytes such as potassium. Prolonged
hyperkalemia has been proposed as a mechanism that
may cause disruption of normal ionic gradients and acti-
vate damaging Ca++-mediated processes, leading to axonal
loss in the setting of ESKD. Krishnan et al. suggest that
the maintenance of serum K+ within normal limits be-
tween dialysis sessions, rather than simple avoidance of
hyperkalemia, is likely to reduce the incidence and severity
of uremic neuropathy [11, 12]. It is reasonable to propose
that a longer and more frequent dialysis regimen should
result in a closer approximation of normal physiological
control of solutes such as potassium.
Conclusion
In summary, uremic neuropathy contributes to the mor-
bidity of patients on dialysis. We report the use of NHD
in a patient with severe debilitating uremic neuropathy.
Prospective evaluation of NHD on clinical evolution of
uremic neuropathy is warranted.
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